pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Imbruvica
drug · small molecule
save

ibrutinib

Marketedupdated 6mo ago
by $ABBV AbbVie Inc.🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $3.5B
2024: $3.5B2024$3.5B
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval240 co-mentions · 60 sources
  • tagSmall Molecule120 co-mentions · 60 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 40 investigational indications.

targets

Tyrosine-protein kinase BTK

all catalysts(0)

nothing on the calendar yet

Trials studying ibrutinib

  • phase3A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)recruitingn=180
  • phase3A 52-week Study of Remibrutinib in IgE-mediated Food Allergyrecruitingn=576
  • phase3A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesactive not recruitingn=409
  • phase2Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphomarecruitingn=30
  • phase1A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participantscompletedn=38
  • —Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemiarecruitingn=180
  • phase2Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)active not recruitingn=23
  • phase3Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.recruitingn=400

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 28, 2026
36 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (448)

  • Jun 14, 2039formulationUS 12201690
  • Sep 3, 2036patentUS 10010507*PED
  • Sep 3, 2036patentUS 10010507*PED
  • Sep 3, 2036patentUS 10010507*PED
  • Sep 3, 2036patentUS 10010507*PED
  • Sep 3, 2036patentUS 10213386*PED
  • Sep 3, 2036patentUS 10213386*PED
  • Sep 3, 2036patentUS 10213386*PED
  • Sep 3, 2036patentUS 10213386*PED
  • Sep 3, 2036patentUS 10828259*PED
  • Sep 3, 2036patentUS 10828259*PED
  • Sep 3, 2036patentUS 10828259*PED
  • Sep 3, 2036patentUS 10828259*PED
  • Sep 3, 2036patentUS 9655857*PED
  • Sep 3, 2036patentUS 9655857*PED
  • Sep 3, 2036patentUS 9655857*PED
  • Sep 3, 2036patentUS 9655857*PED
  • Apr 6, 2036formulationUS 12364698
  • Mar 3, 2036formulationUS 10010507
  • Mar 3, 2036formulationUS 10010507
  • Mar 3, 2036formulationUS 10010507
  • Mar 3, 2036formulationUS 10010507
  • Mar 3, 2036formulationUS 10213386
  • Mar 3, 2036formulationUS 10213386
  • Mar 3, 2036formulationUS 10213386
  • Mar 3, 2036formulationUS 10213386
  • Mar 3, 2036formulationUS 10828259
  • Mar 3, 2036formulationUS 10828259
  • Mar 3, 2036formulationUS 10828259
  • Mar 3, 2036formulationUS 10828259
  • Mar 3, 2036formulationUS 12551448
  • Mar 3, 2036formulationUS 12551448
  • Mar 3, 2036formulationUS 12551448
  • Mar 3, 2036formulationUS 9655857
  • Mar 3, 2036formulationUS 9655857
  • Mar 3, 2036formulationUS 9655857
  • Mar 3, 2036formulationUS 9655857
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10463668*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 10695350*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Apr 24, 2035patentUS 9795604*PED
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2654)US 10463668
  • Oct 24, 2034method-of-use (U-2970)US 10463668
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2970)US 10695350
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2846)US 10695350
  • Oct 24, 2034method-of-use (U-2969)US 9795604
  • Oct 24, 2034method-of-use (U-2969)US 9795604
  • Oct 24, 2034method-of-use (U-2970)US 9795604
  • Oct 24, 2034method-of-use (U-2970)US 9795604
  • Oct 24, 2034method-of-use (U-2970)US 9795604
  • Oct 24, 2034method-of-use (U-2969)US 9795604
  • Oct 24, 2034method-of-use (U-2969)US 9795604
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Apr 30, 2034patentUS 9296753*PED
  • Feb 18, 2034patentUS 9540382*PED
  • Feb 18, 2034patentUS 9540382*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10106548*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10125140*PED
  • Dec 3, 2033patentUS 10294231*PED
  • Dec 3, 2033patentUS 10294231*PED
  • Dec 3, 2033patentUS 10294232*PED
  • Dec 3, 2033patentUS 10294232*PED
  • Dec 3, 2033patentUS 10752634*PED
  • Dec 3, 2033patentUS 10752634*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 10961251*PED
  • Dec 3, 2033patentUS 9713617*PED
  • Dec 3, 2033patentUS 9713617*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Dec 3, 2033patentUS 9725455*PED
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Oct 30, 2033compositionUS 9296753
  • Aug 18, 2033method-of-use (U-1650)US 9540382
  • Aug 18, 2033method-of-use (U-1684)US 9540382
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10106548
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033compositionUS 10125140
  • Jun 3, 2033formulationUS 10294231
  • Jun 3, 2033formulationUS 10294231
  • Jun 3, 2033formulationUS 10294232
  • Jun 3, 2033formulationUS 10294232
  • Jun 3, 2033formulationUS 10752634
  • Jun 3, 2033formulationUS 10752634
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 10961251
  • Jun 3, 2033formulationUS 9713617
  • Jun 3, 2033formulationUS 9713617
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Jun 3, 2033compositionUS 9725455
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10004746*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10016435*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10478439*PED
  • Dec 3, 2031patentUS 10653696*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 10751342*PED
  • Dec 3, 2031patentUS 8754090*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 8999999*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9125889*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801881*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9801883*PED
  • Dec 3, 2031patentUS 9814721*PED
  • Jun 3, 2031method-of-use (U-2241)US 100047464.5y
  • Jun 3, 2031method-of-use (U-3847)US 100047464.5y
  • Jun 3, 2031method-of-use (U-2242)US 100047464.5y
  • Jun 3, 2031method-of-use (U-2242)US 100047464.5y
  • Jun 3, 2031method-of-use (U-1684)US 100047464.5y
  • Jun 3, 2031method-of-use (U-1946)US 100047464.5y
  • Jun 3, 2031method-of-use (U-2241)US 100047464.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-3845)US 100164354.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-1650)US 100164354.5y
  • Jun 3, 2031method-of-use (U-3422)US 104784394.5y
  • Jun 3, 2031method-of-use (U-3845)US 104784394.5y
  • Jun 3, 2031method-of-use (U-3422)US 104784394.5y
  • Jun 3, 2031method-of-use (U-3422)US 104784394.5y
  • Jun 3, 2031method-of-use (U-3422)US 104784394.5y
  • Jun 3, 2031method-of-use (U-1684)US 104784394.5y
  • Jun 3, 2031method-of-use (U-3422)US 104784394.5y
  • Jun 3, 2031method-of-use (U-1456)US 106536964.5y
  • Jun 3, 2031method-of-use (U-2943)US 107513424.5y
  • Jun 3, 2031method-of-use (U-1491)US 107513424.5y
  • Jun 3, 2031method-of-use (U-2943)US 107513424.5y
  • Jun 3, 2031method-of-use (U-2943)US 107513424.5y
  • Jun 3, 2031method-of-use (U-2943)US 107513424.5y
  • Jun 3, 2031method-of-use (U-1491)US 107513424.5y
  • Jun 3, 2031method-of-use (U-3842)US 107513424.5y
  • Jun 3, 2031method-of-use (U-2242)US 116728034.5y
  • Jun 3, 2031method-of-use (U-1946)US 116728034.5y
  • Jun 3, 2031method-of-use (U-2242)US 116728034.5y
  • Jun 3, 2031method-of-use (U-1684)US 116728034.5y
  • Jun 3, 2031method-of-use (U-2242)US 116728034.5y
  • Jun 3, 2031method-of-use (U-3843)US 116728034.5y
  • Jun 3, 2031method-of-use (U-1456)US 87540904.5y
  • Jun 3, 2031method-of-use (U-1491)US 89999994.5y
  • Jun 3, 2031method-of-use (U-1946)US 89999994.5y
  • Jun 3, 2031method-of-use (U-1946)US 89999994.5y
  • Jun 3, 2031method-of-use (U-3844)US 89999994.5y
  • Jun 3, 2031method-of-use (U-1946)US 89999994.5y
  • Jun 3, 2031method-of-use (U-2242)US 89999994.5y
  • Jun 3, 2031method-of-use (U-1683)US 89999994.5y
  • Jun 3, 2031method-of-use (U-1650)US 91258894.5y
  • Jun 3, 2031method-of-use (U-3845)US 91258894.5y
  • Jun 3, 2031method-of-use (U-1745)US 91258894.5y
  • Jun 3, 2031method-of-use (U-1650)US 91258894.5y
  • Jun 3, 2031method-of-use (U-1650)US 91258894.5y
  • Jun 3, 2031method-of-use (U-1650)US 91258894.5y
  • Jun 3, 2031method-of-use (U-1650)US 91258894.5y
  • Jun 3, 2031method-of-use (U-3847)US 98018814.5y
  • Jun 3, 2031method-of-use (U-2242)US 98018814.5y
  • Jun 3, 2031method-of-use (U-2242)US 98018814.5y
  • Jun 3, 2031method-of-use (U-1491)US 98018814.5y
  • Jun 3, 2031method-of-use (U-2242)US 98018814.5y
  • Jun 3, 2031method-of-use (U-1491)US 98018814.5y
  • Jun 3, 2031method-of-use (U-1491)US 98018814.5y
  • Jun 3, 2031method-of-use (U-2243)US 98018834.5y
  • Jun 3, 2031method-of-use (U-2159)US 98018834.5y
  • Jun 3, 2031method-of-use (U-2159)US 98018834.5y
  • Jun 3, 2031method-of-use (U-2159)US 98018834.5y
  • Jun 3, 2031method-of-use (U-3844)US 98018834.5y
  • Jun 3, 2031method-of-use (U-2243)US 98018834.5y
  • Jun 3, 2031method-of-use (U-2159)US 98018834.5y
  • Jun 3, 2031method-of-use (U-1947)US 98147214.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • May 13, 2028patentUS 8008309*PED1.5y
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Nov 13, 2027compositionUS 8008309356d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Oct 26, 2027patentUS 8563563*PED338d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 7514444*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8476284*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8497277*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8697711*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8703780*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8735403*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8754091*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8952015*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 8957079*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Jun 28, 2027patentUS 9181257*PED218d
  • Apr 26, 2027method-of-use (U-1491)US 8563563155d
  • Apr 26, 2027method-of-use (U-1491)US 8563563155d
  • Apr 26, 2027method-of-use (U-2241)US 8563563155d
  • Apr 26, 2027method-of-use (U-3845)US 8563563155d
  • Apr 26, 2027method-of-use (U-1491)US 8563563155d
  • Apr 26, 2027method-of-use (U-2242)US 8563563155d
  • Apr 26, 2027method-of-use (U-1491)US 8563563155d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026compositionUS 751444436d
  • Dec 28, 2026method-of-use (U-1650)US 847628436d
  • Dec 28, 2026method-of-use (U-3845)US 847628436d
  • Dec 28, 2026method-of-use (U-1946)US 847628436d
  • Dec 28, 2026method-of-use (U-2241)US 847628436d
  • Dec 28, 2026method-of-use (U-2241)US 847628436d
  • Dec 28, 2026method-of-use (U-1946)US 847628436d
  • Dec 28, 2026method-of-use (U-1650)US 847628436d
  • Dec 28, 2026method-of-use (U-1650)US 849727736d
  • Dec 28, 2026method-of-use (U-2242)US 849727736d
  • Dec 28, 2026method-of-use (U-3422)US 849727736d
  • Dec 28, 2026method-of-use (U-2970)US 849727736d
  • Dec 28, 2026method-of-use (U-1491)US 849727736d
  • Dec 28, 2026method-of-use (U-3422)US 849727736d
  • Dec 28, 2026method-of-use (U-1456)US 849727736d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026compositionUS 869771136d
  • Dec 28, 2026method-of-use (U-3842)US 870378036d
  • Dec 28, 2026method-of-use (U-2242)US 870378036d
  • Dec 28, 2026method-of-use (U-2242)US 870378036d
  • Dec 28, 2026method-of-use (U-1491)US 870378036d
  • Dec 28, 2026method-of-use (U-1491)US 870378036d
  • Dec 28, 2026method-of-use (U-2242)US 870378036d
  • Dec 28, 2026method-of-use (U-1491)US 870378036d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026compositionUS 873540336d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026formulationUS 875409136d
  • Dec 28, 2026method-of-use (U-1946)US 895201536d
  • Dec 28, 2026method-of-use (U-2241)US 895201536d
  • Dec 28, 2026method-of-use (U-1491)US 895201536d
  • Dec 28, 2026method-of-use (U-1946)US 895201536d
  • Dec 28, 2026method-of-use (U-1491)US 895201536d
  • Dec 28, 2026method-of-use (U-3845)US 895201536d
  • Dec 28, 2026method-of-use (U-1946)US 895201536d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 895707936d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d
  • Dec 28, 2026compositionUS 918125736d

FDA exclusivities (28)

  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Feb 24, 2030PEDPediatric (6mo bonus)3.3y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Feb 24, 2026PEDPediatric (6mo bonus)
  • Aug 24, 2025NPPNew Product (3y)
  • Aug 24, 2025NPNP
  • Aug 24, 2025NPPNew Product (3y)
  • Aug 24, 2025NPPNew Product (3y)
  • Aug 24, 2025NPPNew Product (3y)
  • Aug 24, 2025NPPNew Product (3y)
  • Aug 24, 2025NPPNew Product (3y)

News(6)

  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 4d ago
  • Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
    Nurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.
    fiercebiotech · 1mo ago
  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
  • J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
    biopharma_dive · 4mo ago
  • Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
    Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
    onclive · 6mo ago
  • Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
    Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
    onclive · 6mo ago
brand
Imbruvica
trade names
Imbruvica
generic
ibrutinib
MOA
Tyrosine-protein kinase BTK inhibitor
indication
Follicular Lymphoma
phase
marketed
approved
2013-11-13
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?